Retrophin (NASDAQ:RTRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Thursday.
According to Zacks, “Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company’s approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. “
Other research analysts have also recently issued reports about the company. BMO Capital Markets reaffirmed a “buy” rating and set a $44.00 price objective on shares of Retrophin in a research report on Friday, October 6th. BidaskClub raised Retrophin from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, ValuEngine cut Retrophin from a “hold” rating to a “sell” rating in a research report on Monday, November 20th. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $44.00.
Retrophin (RTRX) opened at $23.18 on Thursday. Retrophin has a 12-month low of $15.55 and a 12-month high of $26.44. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.83 and a current ratio of 3.88. The firm has a market capitalization of $894.00, a PE ratio of -17.56 and a beta of 1.45.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.21). Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. The company had revenue of $40.34 million for the quarter, compared to analysts’ expectations of $40.51 million. During the same period in the previous year, the firm earned ($0.09) earnings per share. The firm’s quarterly revenue was up 18.8% on a year-over-year basis. sell-side analysts predict that Retrophin will post -1.25 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of RTRX. Dimensional Fund Advisors LP lifted its holdings in Retrophin by 49.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 825,253 shares of the biopharmaceutical company’s stock worth $16,002,000 after purchasing an additional 271,551 shares in the last quarter. Macquarie Group Ltd. lifted its holdings in Retrophin by 22.7% in the 3rd quarter. Macquarie Group Ltd. now owns 1,459,218 shares of the biopharmaceutical company’s stock worth $36,320,000 after purchasing an additional 270,399 shares in the last quarter. Prudential Financial Inc. lifted its holdings in Retrophin by 385.7% in the 3rd quarter. Prudential Financial Inc. now owns 194,140 shares of the biopharmaceutical company’s stock worth $4,832,000 after purchasing an additional 154,170 shares in the last quarter. American Century Companies Inc. lifted its holdings in Retrophin by 88.5% in the 3rd quarter. American Century Companies Inc. now owns 285,875 shares of the biopharmaceutical company’s stock worth $7,115,000 after purchasing an additional 134,205 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Retrophin by 8.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,635,234 shares of the biopharmaceutical company’s stock worth $31,707,000 after purchasing an additional 125,695 shares in the last quarter.
TRADEMARK VIOLATION NOTICE: “Retrophin (RTRX) Downgraded to “Sell” at Zacks Investment Research” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/11/retrophin-rtrx-downgraded-to-sell-at-zacks-investment-research.html.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.